Eli Lilly and Company $LLY Shares Sold by Raiffeisen Bank International AG

Raiffeisen Bank International AG lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.0% during the second quarter, HoldingsChannel.com reports. The fund owned 145,246 shares of the company’s stock after selling 21,609 shares during the quarter. Eli Lilly and Company accounts for about 1.7% of Raiffeisen Bank International AG’s holdings, making the stock its 7th biggest position. Raiffeisen Bank International AG’s holdings in Eli Lilly and Company were worth $115,077,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $27,000. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $31,000. Blume Capital Management Inc. grew its holdings in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the period. IMG Wealth Management Inc. bought a new stake in Eli Lilly and Company in the second quarter valued at $35,000. Finally, TD Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LLY. BMO Capital Markets raised their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Guggenheim reissued a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research note on Monday, November 10th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.11.

Eli Lilly and Company Stock Up 0.2%

LLY opened at $1,024.67 on Monday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,033.62. The firm has a market capitalization of $968.70 billion, a P/E ratio of 66.97, a PEG ratio of 1.21 and a beta of 0.43. The company’s 50-day moving average is $826.89 and its 200 day moving average is $779.30. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the business posted $1.18 EPS. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.